Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

397 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The impact of COVID-19 on the diagnosis and treatment of HCC: analysis of a nationwide registry for advanced liver diseases (REAL).
Okushin K, Tateishi R, Hirakawa S, Tachimori H, Uchino K, Nakagomi R, Yamada T, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, Kanto T, Yoshiji H, Izumi N, Kudo M, Koike K. Okushin K, et al. Among authors: hirakawa s. Sci Rep. 2024 Feb 3;14(1):2826. doi: 10.1038/s41598-024-53199-6. Sci Rep. 2024. PMID: 38310156 Free PMC article.
Muscle pathology of antisynthetase syndrome according to antibody subtypes.
Tanboon J, Inoue M, Hirakawa S, Tachimori H, Hayashi S, Noguchi S, Okiyama N, Fujimoto M, Suzuki S, Nishino I. Tanboon J, et al. Among authors: hirakawa s. Brain Pathol. 2023 Jul;33(4):e13155. doi: 10.1111/bpa.13155. Epub 2023 Mar 7. Brain Pathol. 2023. PMID: 36882048 Free PMC article. Review.
Pathologic Features of Anti-Mi-2 Dermatomyositis.
Tanboon J, Inoue M, Hirakawa S, Tachimori H, Hayashi S, Noguchi S, Suzuki S, Okiyama N, Fujimoto M, Nishino I. Tanboon J, et al. Among authors: hirakawa s. Neurology. 2021 Jan 19;96(3):e448-e459. doi: 10.1212/WNL.0000000000011269. Epub 2020 Dec 4. Neurology. 2021. PMID: 33277422
Ifenprodil for the treatment of methamphetamine use disorder: An exploratory, randomized, double-blind, placebo-controlled trial.
Kotajima-Murakami H, Takano A, Hirakawa S, Ogai Y, Funada D, Tanibuchi Y, Ban E, Kikuchi M, Tachimori H, Maruo K, Kawashima T, Tomo Y, Sasaki T, Oi H, Matsumoto T, Ikeda K. Kotajima-Murakami H, et al. Among authors: hirakawa s. Neuropsychopharmacol Rep. 2022 Mar;42(1):92-104. doi: 10.1002/npr2.12232. Epub 2022 Jan 23. Neuropsychopharmacol Rep. 2022. PMID: 35068087 Free PMC article. Clinical Trial.
397 results